Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous CD147-targeted CAR-T cells
- Development stage
- Unknown
- Lead developer
- Air Force Military Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Autologous CD147-targeted CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target **CD147** (also known as Basigin or EMMPRIN). CD147 is a transmembrane glycoprotein that is highly expressed in various hematological and solid tumors, including T-cell non-Hodgkin lymphoma (T-NHL), where it promotes tumor progression and metastasis. Developed by the National Translational Science Center for Molecular Medicine at the **Air Force Medical University**, this therapy involves the genetic modification of a patient's own T cells to express a CAR specific for CD147. In clinical trials (e.g., ChiCTR2100045721), these cells are being evaluated for the treatment of relapsed or refractory CD147-positive T-NHL, often as a bridge to sequential allogeneic hematopoietic stem cell transplantation (allo-HSCT).
- Other names
- Autologous CD147-CART cellsCD147-CARTCD-147-CARTCD 147-CART
02
Targets
BSG (Basigin)
Beyond the preview
Go deeper on autologous CD147-targeted CAR-T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous CD147-targeted CAR-T cells.